Chronic, such as capacity or high volume hyponatremia
Conditions
Interventions
GroupA:PK test of intravenous infusion of a single dose of 10 mg
GroupB:PK PK test. A single dose of intravenous injection of 20 mg, washout period after intravenous injection of 20 mg (loading dose) then slowly intravenous injection of 20 mg 4 times (maintenance d
GroupC:PK test of intravenous infusion of a single dose of 40 mg
Sponsors
Beijing An Zhen Hospital affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: All meet the following criteria can be selected: 1 volunteered to participate in this clinical trial, and signed informed consent 2 China male or female subjects 3 age 18~45 4.Body mass index (BMI) within the scope of the 19 ~ 24 kg/m2, BMI = weight (kg)/height 2 (m2), and not less than 50 kg weight
Exclusion criteria
Exclusion criteria: Following any one who cannot be enrolled in this study: 1 any may affect the safety and drug in the body's disease history 2 Currently has any instability or recurrent disease, or affect the disease in the process of drug in the body 3 screening of blood pressure and heart rate in the following period does not check the normal range: Sitting systolic blood pressure: 90-140 mmHg: 60-90 mmHg, diastolic blood pressure, heart rate less than 100 BPM 4 the serum sodium was higher than 145mmol/l 5 orthostatic hypotension, dizziness or vertigo history history 6. Allergic / hypersensitivity reaction (including the drugs or excipients, food allergies), history of allergy history and specific reaction of benzo aza Zhuo or its derivatives (benazepril) 7 a month before the administration of drugs in clinical trials Participated in other clinical trials in the 8 clinical trials administered within 3 months before or during the test plan to participate in other clinical trials 9 smokers 10 test (during the screening period to the end of follow-up) can't quit smoking 11 alcoholics 12 test (during the screening period to the end of follow-up) cannot abstainer 13 drug abusers, or urine drug screening test positive 14 cannot comply with the diet research center of the 15 in the test within 3 months before the blood donation of more than 200 mL, blood donors testing or during the test, after the end of 1 months 16 in this test administered 1 weeks before or during the test of excessive physical labor or exercise. 17 physical examination, ECG, chest X-ray examination and clinical significance of abnormal 18 laboratory tests (blood routine, urine routine, liver and kidney function, blood glucose, blood lipid, abnormal ion) and the clinical significance. 19 hepatitis B surface antigen, hepatitis C antibody, syphilis antibody, HIV antibody test positive results 20 pregnant or lactating women 21 In addition to the above, the researchers do not consider it appropriate to take the test subjects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood drug concentration; | — |
Countries
China
Contacts
Public ContactLin Yang
Outcome results
None listed